DYRK1A and diabetes mellitus: Challenges like low selectivity, potential off-target effects, and incomplete mechanism insights explain why DYRK1A inhibitors, despite encouraging in vitro and animal model outcomes, have not advanced to clinical trials for diabetes therapy (Wang et al. 2024).